Did you know?
Poor adherence to daily lipid-lowering therapy is a major driver of residual cardiovascular risk. Inclisiran, a small interfering RNA (siRNA) that silences PCSK9 production in the liver, is administered by subcutaneous injection only twice per year after two initial doses. Phase 3 ORION trials (n=3,660 patients across ORION-10, -11, and -9) demonstrated that twice-yearly inclisiran reduced LDL cholesterol by 50–52% from baseline over 18 months, with effects persisting between doses and a safety profile comparable to placebo.
For patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who struggle with adherence to daily oral therapy, how does a twice-yearly injectable PCSK9-silencing approach change your lipid management strategy?
It may improve adherence and provide consistent LDL lowering.
I would consider it alongside lifestyle changes and other guideline-directed lipid therapy.
The key is choosing the treatment that the patient can realistically maintain long term.